Use of inhibitors of bruton's tyrosine kinase (BTK)
DCFirst Claim
Patent Images
1. A method for treating chronic lymphocytic leukemia in an individual who has failed at least one prior therapy for chronic lymphocytic leukemia comprising administering to the individual once per day about 420 mg of an oral dose of an inhibitor of Bruton'"'"'s tyrosine kinase (Btk) having the structure:
5 Assignments
Litigations
0 Petitions
Accused Products
Abstract
Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
153 Citations
18 Claims
- 1. A method for treating chronic lymphocytic leukemia in an individual who has failed at least one prior therapy for chronic lymphocytic leukemia comprising administering to the individual once per day about 420 mg of an oral dose of an inhibitor of Bruton'"'"'s tyrosine kinase (Btk) having the structure:
- 3. A method for treating relapsed or refractory chronic lymphocytic leukemia in an individual comprising administering to the individual in need thereof once per day about 420 mg of an oral dose of an inhibitor of Bruton'"'"'s tyrosine kinase (Btk) having the structure:
Specification